Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. rheumatoid arthritis
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Rheumatoid Arthritis Articles & Analysis

51 news found

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Inhibition of this enzyme can produce therapeutic effects in disease states like cancer, rheumatoid arthritis, and cardiovascular disease. Creative Enzymes is known in the enzyme industry for providing a comprehensive range of enzymes, especially for its hydrolases category. ...

ByCreative Enzymes


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

Autoimmune Diseases: Antibodies are designed to modulate the immune response in conditions like rheumatoid arthritis and multiple sclerosis. 3. Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. ...

ByCD ComputaBio


Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. ...

ByAlfa Chemistry


Galapagos announces changes to Executive Committee

Galapagos announces changes to Executive Committee

Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that ...

ByGalapagos NV


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

“The recommendation by the PRAC reflects the concerns raised by the substance class mainly in older patients with rheumatoid arthritis,” said Dr. Stefan Schreiber, Professor of Medicine and Gastroenterology at the Christian-Albrechts-University in Kiel, Director of the Clinic for Internal Medicine at the University Hospital Schleswig-Holstein and ...

ByGalapagos NV


Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Walid Abi-Saab, Chief Medical officer, at Galapagos said, “We are excited to present data at ACR which highlights our continued commitment to patients and the healthcare provider community, in particular initial data from our first international, real-world arthritis study. We believe that it’s not only important to control disease activity to prevent long term ...

ByGalapagos NV


Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Our most advanced candidate, SIK3 inhibitor ‘4399, has shown strong preclinical evidence for potential in rheumatoid arthritis (RA) (EULAR 20224), with a promising pharmacological and safety profile. ...

ByGalapagos NV


Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in ...

ByGalapagos NV


GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to ...

ByMorphoSys AG


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

“These messages include DNA, RNA, protein and lipid biomarkers found in blood (or other biofluids) that have important applications in research, diagnosis and treatment for cancer, as well as cardiometabolic diseases like heart attack and diabetes, inflammatory diseases such as rheumatoid arthritis and Crohn’s disease, and neurodegenerative diseases ...

ByINOVIQ Ltd


Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life

Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life

The nationally representative survey estimates that more than 72.3 million U.S. adults – 28% of the adult population – suffer from chronic low back pain (CLBP), higher than previously reported1,2, and greater than arthritis (58.5 million),3 diabetes (37.3 million),4 or heart disease (30.3 million).5 More than three-fourths (76%) say CLBP has interfered with their ...

ByVertos Medical, Inc.


Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

It is mentioned in the presentation that "Dysregulated interleukin-6 (IL-6) levels underlie several pathological conditions, such as sepsis, progression of cancer, rheumatoid arthritis, and many other conditions. Prior studies indicate that high levels of IL-6 serve as an early indication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced ...

ByBluejay Diagnostics, Inc.


What Are D-Glucosamines?

What Are D-Glucosamines?

Clinically, active supplementation of glucosamine and chondroitin can relieve the symptoms of arthritis. Therefore, it is widely used to treat osteoarthritis and arthritis pain.D-glucosamine is a monosaccharide containing an amine group instead of a hydroxyl group. ...

ByCD Bioparticles


Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics

Rani conducted a preclinical study of RaniPill HC, with each device containing an 18-mg dose of the biologic adalimumab, a tumor necrosis factor (TNF)-α inhibitor that is approved for multiple autoimmune conditions including rheumatoid arthritis and Crohn’s disease. The unencapsulated RaniPill HC device was placed laparoscopically in the jejunum of ...

ByRani Therapeutics


`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug

`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug

Bilirubin, which causes jaundice in humans, has been in the spotlight as an anti-inflammatory substance since the 1930s. The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the ...

ByBilix Co., Ltd.


Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis

Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis

The multi-cytokines detectable by Creative Proteomics include but are not limited to the following: (1) Cancer Cytokines Assay (2) Cytokine Storm Assays (3) Autoimmune Disease Cytokines Assay (4) Inflammation Cytokines Assay (5) Rheumatoid Arthritis Cytokines Assay (6) Atopic Dermatitis Cytokines Assay (7) Osteoporosis ...

ByCreative Proteomics


Altamira Therapeutics Provides Update on RNA Therapeutics Program

Altamira Therapeutics Provides Update on RNA Therapeutics Program

The project, titled "A Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation," will help to move the Company's OligoPhore™ delivery platform towards clinical stage evaluations in inflammatory disorders by demonstrating safety and effectiveness in a mouse model of rheumatoid arthritis and optimizing a commercially scalable ...

ByAuris Medical AG


Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, ...

ByAptorum Group Limited


SetPoint Medical Appoints Amy Derosier as Vice President of Clinical Affairs

SetPoint Medical Appoints Amy Derosier as Vice President of Clinical Affairs

Chernoff will be invaluable as we advance our rheumatoid arthritis program through the U.S. pivotal study,” commented Murthy Simhambhatla, PhD, President and Chief Executive Officer of SetPoint Medical. ...

BySetpoint Medical Corporation


Focal Healthcare and CIMTEC Sign Licensing Agreement for a Suite of 3D Ultrasound AI-Based Technologies

Focal Healthcare and CIMTEC Sign Licensing Agreement for a Suite of 3D Ultrasound AI-Based Technologies

Some of the first applications to be commercialized include scanning carotid arteries to assess the risk for stroke, the thyroid and breast to determine whether detected nodules may be malignant, and even assessing and monitoring osteoarthritis and rheumatoid arthritis in the knee, wrist or other parts of the body. “CIMTEC is very excited about the ...

ByFocal Healthcare

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT